Biotech News

Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting

Disc Medicine (IRON)Disc Medicine2026-11-04 14:05 ESTClinical readout

Two oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (PV) Oral presentation highlighting inhibition of glycine transporter 1 reduced chronic inflammation

Related news

IRONDisc Medicine2026-05-12 13:30 EST

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

KPTIKaryopharm Therapeutics2026-11-04 14:01 EST

Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)

KPTIKaryopharm Therapeutics2026-04-21 14:32 EST

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

RIGLRigel Pharmaceuticals2026-11-04 14:15 EST

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

GERNGeron2026-10-28 12:00 EST

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

ZNTLZentalis2026-05-21 21:39 EST

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

ZNTLZentalis2026-04-21 14:27 EST

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

SNDXSyndax Pharmaceuticals2026-10-12 20:01 EST

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

APTOAptose Biosciences, Inc.2026-06-15 11:30 EST

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

View all latest news

Disc Medicine

Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO...

Recent company news

IRONDisc Medicine2026-11-05 13:30 EST

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-11-04 14:05 EST

Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting

IRONDisc Medicine2026-11-02 13:30 EST

Disc Medicine to Participate in Upcoming Investor Conferences

IRONDisc Medicine2026-10-21 00:52 EST

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

IRONDisc Medicine2026-10-19 20:01 EST

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

Stock data

Close: 78.47 USD
Market cap: 2.6B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States